Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Aardvark Therapeutics is facing a temporary hold on its Phase 3 clinical trial for ARD-101 due to a QRS prolongation signal in healthy volunteers, but management has reiterated that this carries limited intrinsic arrhythmia risk and is reversible without medical intervention. The preliminary exposure-response modeling suggests lower doses fall below the threshold for QRS effect, giving the company flexibility in the next trial design. Management is confident in their ability to resolve the hold and has positive guidance from the FDA, although no specific timeline has been provided.

Bears say

Aardvark Therapeutics is facing significant risks, including the failure of lifting the clinical hold on ARD-101, negative clinical results from the Phase 3 HERO trial, and the potential partnership and geopolitical risks. Based on a discounted cash flow valuation, the company's total enterprise value is estimated to be $168M, with a corresponding 12-month price objective of $6 per share.

AARD has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 8 analysts, AARD has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.